How is COVID-19 Affecting the FDA? Click here to learn more.
Our agile team of experts is fully mobilized to support you to help keep your operations running smoothly.
How can we help?
Click here to learn more.
ABOUT US
About the Weinberg Group
Our Expertise
Our Mission and Values
Meet Our Team
News and Events
Careers
CONTACT US
PROPHARMA GROUP SITE
Follow
202.833.8077
The World’s Leading FDA Consultants.
MEDICAL DEVICES
Medical Device Meeting Services
Medical Device Submissions
DRUGS & BIOTECH
Regulatory Strategy Consulting
FDA Meetings
Pre-IND Meeting
End of Phase 2 Meeting
Pre-NDA Meeting Guidance
FDA Advisory Committee Meeting
FDA Submissions
IND Submission
NDA Submissions: 505(b)(1) & 505(b)(2)
Orphan Drug Designation
Nonclinical Drug Development
Study Design, Placement, & Monitoring
Discovery Stage Assistance
Results Analysis & Design of Follow On Work
Regulatory Due Diligence
ANDA SUBMISSIONS
QUALITY & COMPLIANCE
Good Clinical Practice (GCP) Services
Good Manufacturing Practices (GMP) Services
Quality Systems & Quality Management
RESOURCES
Home
>
Your inquiry has been received
Your inquiry has been received
Thank you for reaching out to us. We will contact you within two business days.
While you wait, we thought you might enjoy viewing our
Resource Center
.
Contact us today to learn about how
The Weinberg Group can help you.
I HAVE SOME QUESTIONS...
▸
I'D LIKE TO GET STARTED...
▸
Rrecent Posts
view more
▸
October 16, 2020
The Key to Understanding Pricing and Reimbursement in the Nordics
October 6, 2020
10 Things You Need to Know about FDA’s Final Rule on Importing Prescription Drugs from Canada
August 31, 2020
How to Ensure Your Device, Software, and Drug Are Ready for a Pre-Approval Inspection